Tumour measurements on imaging for clinical trial: A national picture of service provision.

Georgina Hopkinson, Jonathan Taylor, Jonathan Wadsley, Angela Darekar, Christina Messiou, Dow-Mu Koh
{"title":"Tumour measurements on imaging for clinical trial: A national picture of service provision.","authors":"Georgina Hopkinson, Jonathan Taylor, Jonathan Wadsley, Angela Darekar, Christina Messiou, Dow-Mu Koh","doi":"10.1038/s44276-025-00131-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiological response evaluation metrics such as RECIST 1.1 inform critical endpoints in oncology trials. The UK was the 6th highest recruiter into oncology trials worldwide between 1999 and 2022, with almost 9000 oncology trials registered during the same period. However, the provision of tumour measurements for oncology trials is often ad hoc and patchy across the NHS. The aim of this work was to understand the barriers to providing an effective imaging tumour measurement service, gain insight into service delivery models and consider the successes and challenges from the perspective of both service providers and end users.</p><p><strong>Methods: </strong>An electronic survey was distributed to those who provide tumour measurement response review for clinical trials (service providers) and those that request and use such measurements in trial activities (service users).</p><p><strong>Results: </strong>Responses from 35 sites demonstrated substantial variation in service provision across the UK. Despite workforce pressures, service is largely delivered through radiologists with a minority utilising radiographer role extension. Only 20% of the service providers had dedicated training and 29% received robust financial reimbursement.</p><p><strong>Discussion: </strong>Service variation is likely a consequence of limited training, education and infrastructure to support robust service, compounded by increasing radiology workload and workforce pressures.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"19"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950641/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJC reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s44276-025-00131-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Radiological response evaluation metrics such as RECIST 1.1 inform critical endpoints in oncology trials. The UK was the 6th highest recruiter into oncology trials worldwide between 1999 and 2022, with almost 9000 oncology trials registered during the same period. However, the provision of tumour measurements for oncology trials is often ad hoc and patchy across the NHS. The aim of this work was to understand the barriers to providing an effective imaging tumour measurement service, gain insight into service delivery models and consider the successes and challenges from the perspective of both service providers and end users.

Methods: An electronic survey was distributed to those who provide tumour measurement response review for clinical trials (service providers) and those that request and use such measurements in trial activities (service users).

Results: Responses from 35 sites demonstrated substantial variation in service provision across the UK. Despite workforce pressures, service is largely delivered through radiologists with a minority utilising radiographer role extension. Only 20% of the service providers had dedicated training and 29% received robust financial reimbursement.

Discussion: Service variation is likely a consequence of limited training, education and infrastructure to support robust service, compounded by increasing radiology workload and workforce pressures.

临床试验肿瘤成像测量:全国服务提供情况。
背景:放射反应评价指标如RECIST 1.1告知肿瘤试验的关键终点。在1999年至2022年期间,英国是全球第六大肿瘤试验招募者,同期注册了近9000项肿瘤试验。然而,在整个NHS中,为肿瘤试验提供的肿瘤测量通常是临时的和不完整的。这项工作的目的是了解提供有效的成像肿瘤测量服务的障碍,深入了解服务交付模式,并从服务提供者和最终用户的角度考虑成功和挑战。方法:对为临床试验提供肿瘤测量反应评价的人员(服务提供者)和在试验活动中要求和使用此类测量的人员(服务使用者)进行电子调查。结果:来自35个站点的回应显示了英国各地服务提供的实质性差异。尽管有劳动力压力,但服务主要是通过放射科医生提供的,少数人利用放射科医生的角色扩展。只有20%的服务提供者进行了专门的培训,29%的人获得了强有力的财务补偿。讨论:服务变化很可能是培训、教育和基础设施有限的结果,以支持强大的服务,再加上不断增加的放射工作量和劳动力压力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信